$ABL
Abacus Life, Inc. Stock $abl

$abl Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000181428723000007 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue	$21.12M	$11.38M	$0.00
YoY Change
Cost Of Revenue	$3.365M	$973.4K
YoY Change	91.75%	46.13%
Gross Profit	$17.76M	$10.41M
YoY Change	82.06%	34.56%
Gross Profit Margin	84.07%	91.45%
Selling, General & Admin	$11.54M	$1.261M
YoY Change	15348.27%	23.06%
% of Gross Profit	65.01%	12.12%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.695M	$1.098K	$0.00
YoY Change	158149.58%	0.0%
% of Gross Profit	9.55%	0.01%
Operating Expenses	$11.46M	$2.035M	$2.163M
YoY Change	28.71%	465.1%	489.65%
Operating Profit	$6.300M	$8.371M
YoY Change	-40.93%	56.94%
Interest Expense	$2.679M	$584.1K	-$908.4K
YoY Change	3.03%	-177.25%	-149.67%
% of Operating Profit	42.53%	6.98%
Other Income/Expense, Net	-$3.539M	-$462.5K	$513.2K
YoY Change	-236.08%	-38.83%
Pretax Income	$2.760M	$7.910M	-$2.559M
YoY Change	-143.81%	-808.68%	-275.01%
Income Tax	$1.710M	$1.185M	-$12.29K
% Of Pretax Income	61.97%	14.98%
Net Earnings	$903.4K	$6.750M	-$2.546M
YoY Change	-114.23%	-695.31%	-274.17%
Net Earnings / Revenue	4.28%	59.32%
Basic Earnings Per Share	$0.01	$0.13
Diluted Earnings Per Share	$0.01	$0.13	-$0.14
COMMON SHARES
Basic Shares Outstanding	62.96M shares	50.51M shares
Diluted Shares Outstanding	63.35M shares	50.51M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.60M	$20.60M	$86.57K
YoY Change	2085.26%	3561.96%	-89.85%
Cash & Equivalents	$36.65M	$20.61M	$86.57K
Short-Term Investments
Other Short-Term Assets	$1.000M	$800.0K	$64.91K
YoY Change	224.39%	1104.46%	-29.16%
Inventory
Prepaid Expenses			$64.91K
Receivables	$1.900M	$10.70M
Other Receivables	$0.00	$100.0K
Total Short-Term Assets	$39.52M	$32.21M	$151.5K
YoY Change	1892.74%	5020.61%	-83.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$261.9K	$177.9K	$18.62K
YoY Change
Goodwill	$140.3M	$140.3M	$0.00
YoY Change
Intangibles	$31.22M	$32.90M	$0.00
YoY Change
Long-Term Investments	$91.80M	$69.20M	$99.22M
YoY Change	-6.57%	-79.94%	-71.24%
Other Assets	$1.000M	$1.802M	$890.8K
YoY Change
Total Long-Term Assets	$264.8M	$245.1M	$99.22M
YoY Change	169.47%	-28.95%	-71.24%
TOTAL ASSETS
Total Short-Term Assets	$39.52M	$32.21M	$151.5K
Total Long-Term Assets	$264.8M	$245.1M	$99.22M
Total Assets	$304.3M	$277.3M	$99.37M
YoY Change	203.56%	-19.76%	-71.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.000K	$401.5K	$4.924M
YoY Change	-99.96%	-73.23%	228.29%
Accrued Expenses	$636.8K	$524.4K	$9.228M
YoY Change	-91.98%	247.92%	6296.72%
Deferred Revenue	$348.8K	$981.2K	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$5.458M	$13.89M	$18.78M
YoY Change	-57.79%	62.67%	9.47%
LONG-TERM LIABILITIES
Long-Term Debt	$118.8M	$91.20M	$0.00
YoY Change
Other Long-Term Liabilities	$3.400M	$2.500M	$0.00
YoY Change	-71.84%	-79.3%	-100.0%
Total Long-Term Liabilities	$122.2M	$93.70M	$0.00
YoY Change	912.01%	675.98%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.458M	$13.89M	$18.78M
Total Long-Term Liabilities	$122.2M	$93.70M	$0.00
Total Liabilities	$138.2M	$116.8M	$18.78M
YoY Change	365.9%	466.71%	-35.75%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.50M	-$29.38M	-$18.41M
YoY Change	3.63%	46.82%	-34.84%
Common Stock			$24.14K
YoY Change			0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$165.8M	$160.1M	-$18.39M
YoY Change
Total Liabilities & Shareholders Equity	$304.3M	$277.3M	$99.37M
YoY Change	203.56%	-19.76%	-71.28%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	$903.4K	$6.750M	-$2.546M
YoY Change	-114.23%	-695.31%	-274.17%
Depreciation, Depletion And Amortization	$1.695M	$1.098K	$0.00
YoY Change	158149.58%	0.0%
Cash From Operating Activities	-$12.82M	-$20.98M	-$626.1K
YoY Change	849.73%	5969.2%	83.83%
INVESTING ACTIVITIES
Capital Expenditures	$100.0K		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$9.730M	-$6.060M	-$962.2K
YoY Change	-96.06%	-2238.92%
Cash From Investing Activities	$9.630M	-$6.060M	-$962.2K
YoY Change	-96.1%	-2238.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	19.22M	27.93M	0.000
YoY Change	-107.86%	619.85%
NET CHANGE
Cash From Operating Activities	-12.82M	-20.98M	-626.1K
Cash From Investing Activities	9.630M	-6.060M	-962.2K
Cash From Financing Activities	19.22M	27.93M	0.000
Net Change In Cash	16.03M	890.0K	-1.588M
YoY Change	1341.13%	-1527.2%	366.33%
FREE CASH FLOW
Cash From Operating Activities	-$12.82M	-$20.98M	-$626.1K
Capital Expenditures	$100.0K		$0.00
Free Cash Flow	-$12.92M		-$626.1K
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	829595	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	116646	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	32206622	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	33282927	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	177931	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18617	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	32900000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2023Q2	us-gaap	Goodwill Goodwill	140287000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	240816	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77011	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	9889610	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	8716111	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	56685617	usd
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	13809352	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	1000000	usd
CY2023Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1600000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1300000	usd
CY2023Q2	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	75582	usd
CY2022Q4	us-gaap	Other Receivable After Allowance For Credit Loss Noncurrent OtherReceivableAfterAllowanceForCreditLossNoncurrent	0	usd
CY2023Q2	abl	State Security Deposits Noncurrent StateSecurityDepositsNoncurrent	206873	usd
CY2022Q4	abl	State Security Deposits Noncurrent StateSecurityDepositsNoncurrent	0	usd
CY2023Q2	abl	Certificates Of Deposit Noncurrent CertificatesOfDepositNoncurrent	262500	usd
CY2022Q4	abl	Certificates Of Deposit Noncurrent CertificatesOfDepositNoncurrent	0	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	890829	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	524400	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	401500	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	40014	usd
CY2023Q2	abl	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	182571	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	185831	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	13894422	usd
CY2023Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	25000000	usd
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	usd
CY2023Q2	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	66165396	usd
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	28249653	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16864	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29268	usd
CY2023Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	9320240	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1363820	usd
CY2023Q2	abl	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	2438600	usd
CY2022Q4	abl	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	0	usd
CY2023Q2	us-gaap	Liabilities Liabilities	116835522	usd
CY2022Q4	us-gaap	Liabilities Liabilities	30945150	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	188641886	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	704963	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29382362	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	25487323	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	877306	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1052836	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	355789	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	899538	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	160498915	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28149697	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	277334437	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59094847	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	354366	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	419422	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	590057	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	990328	usd
CY2023Q2	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	8263499	usd
CY2022Q2	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	5965466	usd
	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	16655833	usd
	us-gaap	Insurance Investment Income InsuranceInvestmentIncome	13980466	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	2760900	usd
CY2022Q2	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	2014013	usd
	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	4339084	usd
	us-gaap	Life Settlement Contracts Fair Value Method Gain Loss LifeSettlementContractsFairValueMethodGainLoss	3305505	usd
CY2023Q2	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	11024399	usd
CY2023Q2	us-gaap	Revenues Revenues	11378765	usd
CY2022Q2	us-gaap	Revenues Revenues	8398901	usd
	us-gaap	Revenues Revenues	21584974	usd
	us-gaap	Revenues Revenues	18276299	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	973400	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	666119	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1462950	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2086075	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	973400	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	666119	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	10405365	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	7732782	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	683841	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1019498	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	577539	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5499	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1274431	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	646705	usd
CY2023Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1445229	usd
CY2022Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-333879	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2398662	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-375513	usd
CY2023Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	672936	usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1039022	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	798156	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1054975	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1098	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1098	usd
	us-gaap	Operating Expenses OperatingExpenses	4289923	usd
	us-gaap	Operating Expenses OperatingExpenses	3728832	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	8370594	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	5333786	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	15832101	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	12461392	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	584075	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	941458	usd
	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7457	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	121601	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-127455	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21651	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-242247	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-462474	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-127455	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-955652	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-242247	usd
CY2023Q2	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	7908120	usd
CY2022Q2	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	5206331	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	14876449	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	12219145	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1184571	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	120132	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	528104	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	296806	usd
	us-gaap	Profit Loss ProfitLoss	14348345	usd
	us-gaap	Profit Loss ProfitLoss	11922339	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-26596	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	406641	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-487303	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	406641	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	6750145	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	4679558	usd
	us-gaap	Net Income Loss NetIncomeLoss	14835648	usd
	us-gaap	Net Income Loss NetIncomeLoss	11515698	usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50507728	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50507728	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50438921	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50438921	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2023Q2	us-gaap	Profit Loss ProfitLoss	6723549	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	5086199	usd
	us-gaap	Profit Loss ProfitLoss	14348345	usd
	us-gaap	Profit Loss ProfitLoss	11922339	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent	-119663	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent	2017559	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent	-231976	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment Attributable To Parent OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent	2017559	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	6603886	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	7103758	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	14116369	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	13939898	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-56111	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1011909	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-543749	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1011909	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6659997	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6091849	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	14660118	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12927989	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5513033	usd
CY2022Q2	us-gaap	Dividends Dividends	310000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2017559	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	5086199	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12306791	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	35662180	usd
CY2023Q2	us-gaap	Dividends Dividends	34451607	usd
CY2023Q2	abl	Stockholders Equity Deferred Transaction Costs StockholdersEquityDeferredTransactionCosts	10841551	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	960900	usd
CY2023Q2	abl	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	-2796225	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	165361332	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	766893	usd
	us-gaap	Dividends Dividends	2400000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2017559	usd
	us-gaap	Profit Loss ProfitLoss	11922339	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12306791	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28149697	usd
	us-gaap	Dividends Dividends	34451607	usd
	abl	Stockholders Equity Deferred Transaction Costs StockholdersEquityDeferredTransactionCosts	10841551	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	960900	usd
	abl	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	-2796225	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	165361332	usd
	us-gaap	Profit Loss ProfitLoss	14348345	usd
	us-gaap	Profit Loss ProfitLoss	11922339	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2141	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2141	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	798156	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1054975	usd
	us-gaap	Life Settlement Contracts Fair Value Method Unrealized Gain Loss LifeSettlementContractsFairValueMethodUnrealizedGainLoss	3319588	usd
	us-gaap	Life Settlement Contracts Fair Value Method Unrealized Gain Loss LifeSettlementContractsFairValueMethodUnrealizedGainLoss	3305505	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2398662	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-375513	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	252659	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	999927	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	384	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	193462	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1379579	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	105655	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	361486	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	0	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-725685	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	402363	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	72938	usd
	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	39556677	usd
	abl	Life Settlement Contract Purchased Fair Value Method LifeSettlementContractPurchasedFairValueMethod	7211509	usd
	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	11374605	usd
	abl	Life Settlement Contract Purchased Investment Method LifeSettlementContractPurchasedInvestmentMethod	7204753	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38364171	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4751170	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	300000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
	abl	Proceeds Due From Payments Due To Affiliates ProceedsDueFromPaymentsDueToAffiliates	-6760627	usd
	abl	Proceeds Due From Payments Due To Affiliates ProceedsDueFromPaymentsDueToAffiliates	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7060627	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-250000	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	35206351	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	9463779	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	10841551	usd
	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	0	usd
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	23533072	usd
	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	2400000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	25000000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	usd
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	10151369	usd
	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	680375	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	35983097	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7744154	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9441701	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2742984	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30052823	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102421	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20611122	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2845405	usd
	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Organization and Merger</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Abacus Life, Inc. (“the Company”) was formerly known as East Resources Acquisition Company ("ERES”), a blank check company incorporated in Delaware on May 22, 2020. Abacus Life, Inc. conducts its business through its wholly-owned, consolidated subsidiaries, primarily Abacus Settlements LLC (“Abacus”) and Longevity Market Assets, LLC (“LMA”), which are incorporated in the state of Delaware (collectively, the “Companies”). On June 30, 2023, (the “Closing Date”), ERES, Longevity Market Assets, LLC and Abacus Settlements, LLC consummated the combining of the Companies as contemplated by the Merger Agreement dated as of August 30, 2022 (as amended on October 14, 2022 and April 20, 2023) with LMA Merger Sub, LLC, a wholly owned subsidiary of ERES (“LMA Merger Sub”), Abacus Merger Sub, LLC, a wholly owned subsidiary of ERES (“Abacus Merger Sub”), Longevity Market Assets, LLC (“LMA”) and Abacus Settlements, LLC (“Legacy Abacus” and, together with LMA, the “Legacy Companies”). Pursuant to the Merger Agreement, on June 30, 2023, (i) LMA Merger Sub merged with and into LMA, with LMA surviving such merger (the “LMA Merger”) and (ii) Abacus Merger Sub merged with and into Legacy Abacus, with Legacy Abacus surviving such merger (the “Abacus Merger” and, together with the LMA Merger, the “Mergers” and, along with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and the Legacy Companies became direct wholly owned subsidiaries of Abacus and ERES changed its name to Abacus Life, Inc. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated assets, liabilities and statements of operations and comprehensive income prior to the Business Combination are those of legacy LMA. The stocks and corresponding capital amounts and income per stock, prior to the Business Combination, have been retroactively restated based on stocks reflecting the exchange ratio established in the Business Combination. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Activity</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company, through its LMA subsidiary, is a provider of services pertaining to life insurance settlements and offers policy servicing to owners and purchasers of life settlement assets, as well as consulting, valuation, and actuarial services. The Company is also engaged in buying and selling of life settlement policies in which it uses its own capital, and purchases life settlement contracts with the intent to either hold to maturity to receive the associated death claim payout or to sell to another purchaser of life settlement contracts for a gain on the sale.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company, through its Abacus subsidiary, also is an originator of outstanding life insurance policies as a licensed life settlement provider on behalf of investors (“Financing Entities”). Abacus locates and screens policies for eligibility as a commercially desirable life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known, collectively, as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less </span></div>than two years. The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account.
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	abl	Number Of Providers Involved In Option Agreement NumberOfProvidersInvolvedInOptionAgreement	2	provider
CY2021Q4	abl	Number Of Unaffiliated Investors Involved In Variable Interest Entity Ownership NumberOfUnaffiliatedInvestorsInvolvedInVariableInterestEntityOwnership	3	investor
CY2021Q4	abl	Number Of Unaffiliated Investors Involved In Variable Interest Entity Ownership NumberOfUnaffiliatedInvestorsInvolvedInVariableInterestEntityOwnership	3	investor
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	122	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	45	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	195205585	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	56685617	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	39520877	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	9889610	usd
CY2022Q4	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	53	insurance_contract
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, disclosure of contingent assets and liabilities at the date of financial statements, and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and </span>assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, purchase price allocation, the selection of useful lives of property and equipment, valuation of other receivables, valuation of life settlement policies, valuation of other investments and available-for-sale securities, valuation of long-term debt, impairment testing, income taxes, and legal reserves.
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	35	insurance_contract
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	18	insurance_contract
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	40092154	usd
CY2022Q4	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	13809352	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	42330000	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	8716111	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentrations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable, and available-for-sale securities. The Company maintains its cash in bank deposit accounts with high-quality financial institutions, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. For accounts receivable, the Company is exposed to credit risk in the event of nonpayment by customers to the extent of the amounts recorded on the accompanying condensed consolidated balance sheets. The Company extends different levels of credit to its customers and maintains allowance for doubtful accounts based upon the expected collectability of accounts receivable. The Company’s procedures for determining this allowance includes evaluating individual customer receivables, considering a customer’s financial condition, monitoring credit history and current economic conditions, and using historical experience applied to an aging of accounts.</span>
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2023Q2	abl	Life Settlement Contracts Number Of Contracts LifeSettlementContractsNumberOfContracts	167	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInRemainderOfFiscalYear	0	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMethodFaceValueMaturingInRemainderOfFiscalYear	0	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsFairValueMaturingInRemainderOfFiscalYear	0	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInNextTwelveMonths	10	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMethodFaceValueMaturingInNextTwelveMonths	12314000	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Maturing In Next Twelve Months LifeSettlementContractsFairValueMaturingInNextTwelveMonths	6855769	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Two LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearTwo	11	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Two LifeSettlementContractsFairValueMethodFaceValueMaturingInYearTwo	16886778	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Two LifeSettlementContractsFairValueMaturingInYearTwo	10530949	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Three LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearThree	10	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Three LifeSettlementContractsFairValueMethodFaceValueMaturingInYearThree	33631467	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Three LifeSettlementContractsFairValueMaturingInYearThree	9174200	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts Maturing In Year Four LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearFour	13	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Face Value Maturing In Year Four LifeSettlementContractsFairValueMethodFaceValueMaturingInYearFour	18755193	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Maturing In Year Four LifeSettlementContractsFairValueMaturingInYearFour	7564469	usd
CY2023Q2	abl	Life Settlement Contract Fair Value Method Number Of Contracts Maturity After Year Four LifeSettlementContractFairValueMethodNumberOfContractsMaturityAfterYearFour	78	insurance_contract
CY2023Q2	abl	Life Settlement Contract Fair Value Method Face Value Maturity After Year Four LifeSettlementContractFairValueMethodFaceValueMaturityAfterYearFour	113618147	usd
CY2023Q2	abl	Life Settlement Contract Fair Value Maturity After Year Four LifeSettlementContractFairValueMaturityAfterYearFour	22560230	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Number Of Contracts LifeSettlementContractsFairValueMethodNumberOfContracts	122	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Face Value LifeSettlementContractsFairValueMethodFaceValue	195205585	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	56685617	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInRemainderOfFiscalYear	0	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodFaceValueMaturingInRemainderOfFiscalYear	0	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInRemainderOfFiscalYear	0	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths	0	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths	0	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Next Twelve Months LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInNextTwelveMonths	0	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Two LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo	2	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Two LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo	4400000	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Two LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearTwo	2131679	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Three LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree	4	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Three LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree	4100000	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Three LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearThree	1281524	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts Maturing In Year Four LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour	4	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Face Value Maturing In Year Four LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour	1362000	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount Maturing In Year Four LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearFour	518736	usd
CY2023Q2	abl	Life Settlement Contract Investment Method Number Of Contracts Maturity After Year Four LifeSettlementContractInvestmentMethodNumberOfContractsMaturityAfterYearFour	35	insurance_contract
CY2023Q2	abl	Life Settlement Contract Investment Method Face Value Maturity After Year Four LifeSettlementContractInvestmentMethodFaceValueMaturityAfterYearFour	29658877	usd
CY2023Q2	abl	Life Settlement Contract Investment Method Amount Maturity After Year Four LifeSettlementContractInvestmentMethodAmountMaturityAfterYearFour	5957671	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Number Of Contracts LifeSettlementContractsInvestmentMethodNumberOfContracts	45	insurance_contract
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Face Value LifeSettlementContractsInvestmentMethodFaceValue	39520877	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	9889610	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Remainder Of Fiscal Year LifeSettlementContractsInvestmentMethodPremiumsToBePaidInRemainderOfFiscalYear	1024151	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Next Twelve Months LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths	1243423	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Two LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo	1310936	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Premiums To Be Paid In Year Three LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree	1044640	usd
CY2023Q2	abl	Life Settlement Contract Investment Method Premium To Be Paid After Year Three LifeSettlementContractInvestmentMethodPremiumToBePaidAfterYearThree	3288619	usd
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Five Year Disclosure Premiums To Be Paid LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid	7911769	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	186801	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25346	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8870	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6729	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	177931	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	18617	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1098	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1098	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2141	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2141	usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-242247	usd
CY2023Q2	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-584075	usd
CY2022Q2	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	0	usd
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-934001	usd
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	32900000	usd
CY2021Q4	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.06
CY2021Q4	abl	Debt Securities Available For Sale Equity Financing Threshold In Which Shares Convert DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert	1000000	usd
CY2022Q4	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	500000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.08
CY2022Q4	abl	Debt Securities Available For Sale Equity Financing Threshold In Which Shares Convert DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert	5000000	usd
CY2022Q4	abl	Debt Securities Available For Sale Equity Financing Threshold In Which Shares Convert DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert	1000000	usd
CY2023Q2	abl	Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held NumberOfEntitiesInWhichEquitySecuritiesWithoutReadilyDeterminableFairValueAreHeld	2	entity
CY2023Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
CY2022Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	0	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2023Q2	us-gaap	Revenues Revenues	11378765	usd
CY2022Q2	us-gaap	Revenues Revenues	8398901	usd
	us-gaap	Revenues Revenues	21584974	usd
	us-gaap	Revenues Revenues	18276299	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	10405365	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	7732782	usd
	us-gaap	Gross Profit GrossProfit	20122024	usd
	us-gaap	Gross Profit GrossProfit	16190224	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	683841	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1019498	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1412845	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1649498	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	577539	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5499	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1274431	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	646705	usd
CY2023Q2	us-gaap	Depreciation Depreciation	1098	usd
CY2022Q2	us-gaap	Depreciation Depreciation	1098	usd
	us-gaap	Depreciation Depreciation	2141	usd
	us-gaap	Depreciation Depreciation	2141	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	121601	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-127455	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-21651	usd
	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	0	usd
CY2023Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1445229	usd
CY2022Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-333879	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2398662	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-375513	usd
CY2023Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	672936	usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1039022	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	798156	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1054975	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1184571	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	120132	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	528104	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	296806	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-26596	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	406641	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-487303	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	406641	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	6750145	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	4679558	usd
	us-gaap	Net Income Loss NetIncomeLoss	14835648	usd
	us-gaap	Net Income Loss NetIncomeLoss	11515698	usd
CY2023Q2	abl	Number Of Providers Involved In Option Agreement NumberOfProvidersInvolvedInOptionAgreement	2	provider
CY2023Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	9889610	usd
CY2022Q4	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	8716111	usd
CY2023Q2	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	53987508	usd
	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Positive Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate	-2698109	usd
CY2023Q2	us-gaap	Life Settlement Contracts Fair Value Method Carrying Amount LifeSettlementContractsFairValueMethodCarryingAmount	56685617	usd
CY2023Q2	abl	Sensitivity Analysis Of Fair Value Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	59857879	usd
	abl	Sensitivity Analysis Of Fair Value Change In Life Settlement Contracts Fair Value Impact Of2 Percent Adverse Change In Discount Rate SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate	3172262	usd
CY2023Q2	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	1602042	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	90148	usd
CY2023Q2	abl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest	29515	usd
CY2023Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-1445229	usd
	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-2705918	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome	175530	usd
	abl	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Equity Attributable To Noncontrolling Interest FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest	56446	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2398662	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	28249653	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	35209825	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-2398662	usd
	us-gaap	Fair Value Option Credit Risk Gains Losses On Assets FairValueOptionCreditRiskGainsLossesOnAssets	-307256	usd
	abl	Fair Value Option Change In Fair Value Gain Loss And Credit Risk Gains Losses On Assets FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets	-2705918	usd
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	66165396	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	250000	usd
CY2022Q4	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	500000	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1000000	usd
CY2023Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1600000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	1300000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	abl	Number Of Votes Per Common Share NumberOfVotesPerCommonShare	1	vote
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62961688	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62961688	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2022	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	13075	usd
CY2022Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2577	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	25315	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	8048	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1184571	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	120132	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.150
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.120
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	528104	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	296806	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.036
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	240816	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	77011	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	227561	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	48127	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16864	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	29268	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	244425	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	77395	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	12471	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	11921	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	24942	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	23842	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	7704	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	612	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	8925	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	1223	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	20175	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	12533	usd
	us-gaap	Lease Cost LeaseCost	33867	usd
	us-gaap	Lease Cost LeaseCost	25065	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	24557	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	23842	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y6M29D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0354
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0336
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	130176	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	118057	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q2	abl	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	248233	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3808	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	244425	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	6750145	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	4679558	usd
	us-gaap	Net Income Loss NetIncomeLoss	14835648	usd
	us-gaap	Net Income Loss NetIncomeLoss	11515698	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50507728	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50507728	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50438921	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50438921	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50369350	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50369350	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.13
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29

Files In Submission

Name	View Source	Status
0001814287-23-000007-index-headers.html	Edgar Link	pending
0001814287-23-000007-index.html	Edgar Link	pending
0001814287-23-000007.txt	Edgar Link	pending
0001814287-23-000007-xbrl.zip	Edgar Link	pending
abl-20230630.htm	Edgar Link	pending
abl-20230630.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
abl-20230630_cal.xml	Edgar Link	unprocessable
abl-20230630_lab.xml	Edgar Link	unprocessable
abl-20230630_def.xml	Edgar Link	unprocessable
abl-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
abl-20230630_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABL
Abacus Life, Inc. Stock $abl

2023 Q3 Form 10-Q Financial Statement

#000181428723000007 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABL Abacus Life, Inc. Stock $abl

2023 Q3 Form 10-Q Financial Statement

#000181428723000007 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABL
Abacus Life, Inc. Stock $abl